CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

Changes of Management Board per April

CHEPLAPHARM is delighted to announce an addition to its board of management.

With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D. joins the company´s management board as Chief Corporate Investment Officer (CIO).

Dr. Parssanedjad is an entrepreneurial healthcare leader, who has more than 15 years of hands-on experience in both building, managing as well as investing into innovative, high-growth healthcare and life science businesses. 

Dr. Parssanedjad joins CHEPLAPHARM from McKinsey&Company, where he has been a co-leader of McKinsey’s global Leap practice in healthcare and life sciences focussing on business building with leading global clients. Previously, he held leadership roles at Merck Group. Dr. Parssanedjad is a trained physician and obtained his medical degree in the field of cancer research /gene therapy.

With this addition, CHEPLAPHARM further strengthens its management board by building on its core competence of corporate investments.

Investor Relations topics

Back to top expand_less